Market Place
Sourcing Support
Robbins LLP Urges Uniqure N.V. Stockholders To Join Class Action
04 Apr 2026 //
PHARMIWEB
UniQure To Report 2025 Financial Results
23 Feb 2026 //
GLOBENEWSWIRE
Rosen Law Firm Urges uniQure Shareholders to Contact Firm
11 Feb 2026 //
PHARMIWEB
Uniqure Reveals Q3 2025 Financials And Corporate Update
10 Nov 2025 //
GLOBENEWSWIRE
Uniqure Secures $125M Non-Dilutive Funding, Refinances $50M Debt
24 Sep 2025 //
GLOBENEWSWIRE
UniQure`s Q2 2025 Financial Results & Progress Highlights
29 Jul 2025 //
GLOBENEWSWIRE
uniQure Appoints Kylie O’Keefe as Chief Customer Officer
11 Jun 2025 //
GLOBENEWSWIRE
uniQure Announces 2024 Financial Results and Recent Progress
27 Feb 2025 //
GLOBENEWSWIRE
uniQure Announces Pricing of its Public Offering
08 Jan 2025 //
GLOBENEWSWIRE
UniQure, Arbutus, HilleVax Announce Layoffs
01 Aug 2024 //
FIERCE BIOTECH
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
23 Jul 2024 //
GLOBENEWSWIRE
Genezen to Acquire uniQure’s Commercial Gene Therapy Operations in Lexington
02 Jul 2024 //
CONTRACT PHARMA
UniQure, with sale of plant, outsources Hemgenix manufacturing
02 Jul 2024 //
BIOPHARMADIVE
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
01 Jul 2024 //
GLOBENEWSWIRE
uniQure Announces Q1 2024 Results And Company Progress
07 May 2024 //
GLOBENEWSWIRE
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
28 Feb 2024 //
GLOBENEWSWIRE
uniQure Announces Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
CSL and uniQure Win 2023 Prix Galien USA Award
27 Oct 2023 //
PR NEWSWIRE
uniQure Announces Second Quarter 2023 Financial Results
01 Aug 2023 //
GLOBENEWSWIRE
UniQure sells part of Hemgenix royalty for $400M cash
16 May 2023 //
ENDPTS
uniQure Announces1Q 2023 FYR and Highlights Recent Company Progress
09 May 2023 //
GLOBENEWSWIRE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Mar 2023 //
GLOBENEWSWIRE
uniQure to Participate in Multiple Upcoming Industry Conferences in March
02 Mar 2023 //
GLOBENEWSWIRE
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
27 Feb 2023 //
GLOBENEWSWIRE
uniQure Announces HOPE-B Trial Data Published in New England Journal of Medicine
23 Feb 2023 //
GLOBENEWSWIRE
First Gene Therapy for Hemophilia B, CSL`s HEMGENIX, Approved by EC
21 Feb 2023 //
PR NEWSWIRE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Dec 2022 //
GLOBENEWSWIRE
uniQure announces positive CHMP opinion for etranacogene dezaparvovec
16 Dec 2022 //
GLOBENEWSWIRE
CSL`s hemophilia B gene therapy works well through 24 months
12 Dec 2022 //
FIERCEPHARMA
Bristol Myers scraps uniQure cardiovascular gene therapy pact
30 Nov 2022 //
FIERCEBIOTECH
FDA approves first gene therapy for hemophilia B
23 Nov 2022 //
BIOPHARMADIVE
Australia`s CSL prices hemophilia gene therapy at $3.5 million
22 Nov 2022 //
REUTERS
uniQure to Host Virtual Research & Development Event on Tuesday
17 Nov 2022 //
GLOBENEWSWIRE
UniQure set to resume dosing in open-label Huntington`s trial
02 Nov 2022 //
FIERCEBIOTECH
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting (ESGCT)
11 Oct 2022 //
GLOBENEWSWIRE
uniQure to Participate in Upcoming Industry Conferences in October
03 Oct 2022 //
GLOBENEWSWIRE
uniQure to Participate in Upcoming Industry Conferences in September
06 Sep 2022 //
GLOBENEWSWIRE
3 patients hospitalized in uniQure Huntington`s disease trial
09 Aug 2022 //
FIERCEBIOTECH
uniQure Announces Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
uniQure shares spike on Huntington`s gene therapy data
24 Jun 2022 //
FIERCEBIOTECH
uniQure: Update on Low-Dose Cohort in PI/II Trial of AMT-130 Gene Therapy
23 Jun 2022 //
GLOBENEWSWIRE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Jun 2022 //
GLOBENEWSWIRE
CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review
25 May 2022 //
BIOSPACE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 May 2022 //
GLOBENEWSWIRE
uniQure Announces First Quarter 2022 Financial Results
02 May 2022 //
GLOBENEWSWIRE
uniQure Announces Multiple Presentations at Upcoming ASGCT
02 May 2022 //
GLOBENEWSWIRE
uniQure Completes Enrollment in First Two Cohorts of Phase I/II Trial of AMT-130
21 Mar 2022 //
GLOBENEWSWIRE
uniQure Announces 2021 Financial Results and Highlights Recent Company Progress
25 Feb 2022 //
GLOBENEWSWIRE
uniQure Announces Dosing in EU Open-Label Trial of AMT-130 Gene Therapy
07 Feb 2022 //
GLOBENEWSWIRE
uniQure Reports Positive Findings Thus Far in Huntington’s Disease Study
27 Dec 2021 //
TRIALSITENEWS
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial
16 Dec 2021 //
GLOBENEWSWIRE
uniQure & CSL Behring Announce Primary Endpoint Achieved in HOPE-B
09 Dec 2021 //
GLOBENEWSWIRE
UniQure, CSL Behring dash to the FDA with a potential blockbuster gene therapy
09 Dec 2021 //
ENDPTS
uniQure to Participate in Upcoming Industry Conferences in November
01 Nov 2021 //
GLOBENEWSWIRE
uniQure Announces Presentations at the Annual Meeting of (ESGCT)
19 Oct 2021 //
GLOBENEWSWIRE
uniQure Announces Completion of Additional Patient Procedures of AMT-130
30 Aug 2021 //
GLOBENEWSWIRE
uniQure Announces Presentations at Upcoming ISTH Virtual Congress
02 Jul 2021 //
GLOBENEWSWIRE
UniQure opens the pocketbook to refresh the pipeline
23 Jun 2021 //
ENDPTS
uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy
23 Jun 2021 //
BIOSPACE
